PL1919904T3 - Makrocykliczne inhibitory wirusa zapalenia wątroby typu C - Google Patents

Makrocykliczne inhibitory wirusa zapalenia wątroby typu C

Info

Publication number
PL1919904T3
PL1919904T3 PL06778068T PL06778068T PL1919904T3 PL 1919904 T3 PL1919904 T3 PL 1919904T3 PL 06778068 T PL06778068 T PL 06778068T PL 06778068 T PL06778068 T PL 06778068T PL 1919904 T3 PL1919904 T3 PL 1919904T3
Authority
PL
Poland
Prior art keywords
hepatitis
virus
macrocyclic inhibitors
macrocyclic
inhibitors
Prior art date
Application number
PL06778068T
Other languages
English (en)
Inventor
Pierre Jean-Marie Bernard Raboisson
Kock Herman Augustinus De
Ismet Dorange
Sandrine Marie Helene Vendeville
Dominique Louis Nestor Ghislain Surleraux
Abdellah Tahri
Yvan Simonnet
De Vreken Wim Van
Lili Hu
Kenneth Alan Simmen
Karl Magnus Nilsson
Bengt Bertil Samuelsson
Åsa Annica Kristina Rosenquist
Hans Kristian Wallberg
Original Assignee
Janssen R&D Ireland
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35595655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1919904(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen R&D Ireland, Medivir Ab filed Critical Janssen R&D Ireland
Publication of PL1919904T3 publication Critical patent/PL1919904T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL06778068T 2005-07-29 2006-07-28 Makrocykliczne inhibitory wirusa zapalenia wątroby typu C PL1919904T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05107069 2005-07-29
EP06778068.4A EP1919904B1 (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis c virus
PCT/EP2006/064815 WO2007014921A1 (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
PL1919904T3 true PL1919904T3 (pl) 2014-06-30

Family

ID=35595655

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06778068T PL1919904T3 (pl) 2005-07-29 2006-07-28 Makrocykliczne inhibitory wirusa zapalenia wątroby typu C

Country Status (13)

Country Link
US (1) US8012939B2 (pl)
EP (1) EP1919904B1 (pl)
JP (1) JP5171624B2 (pl)
CN (1) CN101273030B (pl)
AR (1) AR054882A1 (pl)
BR (1) BRPI0614638A2 (pl)
DK (1) DK1919904T3 (pl)
ES (1) ES2456617T3 (pl)
MY (1) MY139988A (pl)
PL (1) PL1919904T3 (pl)
RU (1) RU2437886C2 (pl)
TW (1) TWI393723B (pl)
WO (1) WO2007014921A1 (pl)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
KR20120090077A (ko) 2004-01-30 2012-08-16 얀센 알 앤드 디 아일랜드 Ｈｃｖ ｎｓ?３ 세린 프로테아제 저해제
DK1919899T3 (da) * 2005-07-29 2011-08-01 Tibotec Pharm Ltd Makrocykliske inhibitorer af hepatitis C virus
PE20070210A1 (es) * 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
ES2373685T3 (es) 2005-07-29 2012-02-07 Tibotec Pharmaceuticals Inhibidores macrocíclicos del virus de la hepatitis c.
TWI412535B (zh) 2005-07-29 2013-10-21 Tibotec Pharm Ltd Ｃ型肝炎病毒之大環抑制劑（五）
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
PL1919898T3 (pl) * 2005-07-29 2011-06-30 Tibotec Pharm Ltd Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
PE20070343A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2661338C (en) * 2006-11-17 2015-05-12 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8426360B2 (en) * 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
WO2009070692A1 (en) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
US8283309B2 (en) 2007-12-20 2012-10-09 Enanta Pharmaceuticals, Inc. Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
CA2719008A1 (en) 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101580535B (zh) * 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201034663A (en) * 2008-12-19 2010-10-01 Gilead Sciences Inc HCV NS3 protease inhibitors
TW201026715A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside phosphoramidates
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
BRPI0923393B1 (pt) * 2008-12-23 2018-06-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. "processos para preparar um inibidor de protease de hcv macrocíclico e intermediários e uso".
JP6104504B2 (ja) 2008-12-23 2017-03-29 ギリアド ファーマセット エルエルシー ヌクレオシド類似体
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
CL2011000716A1 (es) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
WO2012092411A2 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SI2709613T2 (sl) 2011-09-16 2020-12-31 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Postopki za zdravljenje HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
SI2909205T1 (sl) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ729172A (en) 2013-01-31 2018-06-29 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69305093T2 (de) 1992-12-29 1997-04-17 Abbott Lab Inhibitoren der retroviralen protease
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
CZ298463B6 (cs) 1996-04-23 2007-10-10 Vertex Pharmaceuticals Incorporated Deriváty mocoviny pro použití jako inhibitory IMPDH enzymu a farmaceutické prostredky, které je obsahují
CZ298749B6 (cs) 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
AU6701598A (en) 1997-03-14 1998-09-29 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
SK13332001A3 (sk) 1999-03-19 2002-02-05 Vertex Pharmaceuticals Incorporated Inhibítory IMPDH enzýmu a ich použitie
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
JP2005535574A (ja) 2002-04-11 2005-11-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特にｈｃｖｎｓ３−ｎｓ４ａプロテアーゼのインヒビター
AU2004211637C1 (en) 2003-02-07 2010-08-19 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
EP1629000B1 (en) * 2003-04-16 2009-02-18 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
KR20120090077A (ko) * 2004-01-30 2012-08-16 얀센 알 앤드 디 아일랜드 Ｈｃｖ ｎｓ?３ 세린 프로테아제 저해제
ES2373685T3 (es) * 2005-07-29 2012-02-07 Tibotec Pharmaceuticals Inhibidores macrocíclicos del virus de la hepatitis c.
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
CA2661338C (en) * 2006-11-17 2015-05-12 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus

Also Published As

Publication number Publication date
JP5171624B2 (ja) 2013-03-27
EP1919904A1 (en) 2008-05-14
BRPI0614638A2 (pt) 2011-04-12
DK1919904T3 (da) 2014-04-07
AR054882A1 (es) 2007-07-25
JP2009502884A (ja) 2009-01-29
CN101273030B (zh) 2012-07-18
MY139988A (en) 2009-11-30
TW200745118A (en) 2007-12-16
EP1919904B1 (en) 2014-01-08
TWI393723B (zh) 2013-04-21
RU2008107727A (ru) 2009-09-10
RU2437886C2 (ru) 2011-12-27
US20090281141A1 (en) 2009-11-12
CN101273030A (zh) 2008-09-24
ES2456617T3 (es) 2014-04-23
US8012939B2 (en) 2011-09-06
WO2007014921A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
AP2585A (en) Macrocyclic inhibitors of hepatitis C virus
AP2473A (en) Macrocyclic inhibitors of hepatitis C virus
IL240244A0 (en) Macrocyclic inhibitors of hepatitis c virus
SI1912997T1 (sl) Makrociklični inhibitorji virusa hepatitis C
SI1919898T1 (sl) Makrociklični inhibitorji virusa hepatitisa C
IL188281A0 (en) Macrocyclic inhibitors of hepatitis c virus
PL1913015T3 (pl) Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
SI1919899T1 (sl) Makrociklični inhibitorji virusa hepatitisa C
IL221361A0 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
ZA200800859B (en) Macrocyclic inhibitors of hepatitis C virus
ZA200800860B (en) Macrocyclic inhibitors of hepatitis C virus
ZA200800856B (en) Macrocyclic inhibitors of hepatitis C virus
ZA200800715B (en) Novel macrocyclic inhibitors of hepatitis C virus replication